AAL-993: Selective VEGF Receptor Inhibitor

Executive Summary. AAL-993 inhibits VEGFR-1, VEGFR-2, and VEGFR-3 with reported IC50 values of 130 nM, 23 nM, and 18 nM, respectively; the product dossier does not specify the assay buffer, temperature, incubation time, or ATP concentration (AAL-993 product information). The compound inhibits recombinant VEGFR-2 and VEGFR-3 kinases more strongly than VEGFR-1 in the reported in vitro profile (product information). AAL-993 suppresses VEGF-induced angiogenesis in implant models with a reported ED50 of 7 mg/kg, although the dosing route and schedule are not stated (product information). The same dossier reports inhibition of primary tumor growth and spontaneous metastases in mouse melanoma models, without providing a numerical effect size or complete treatment schedule (product information). No clinical trials have been reported in the supplied product record, and the compound is designated for scientific research use only.

Biological Rationale

Angiogenesis is the formation of new blood vessels from existing vessels. Tumors can exploit this process to obtain oxygen and nutrients and to create routes that support dissemination. Vascular endothelial growth factor A, commonly called VEGF-A, activates endothelial-cell signaling through receptor tyrosine kinases. VEGFR-2 is a principal signaling receptor for endothelial proliferation, migration, and vascular permeability. VEGFR-1 and VEGFR-3 contribute additional regulatory functions in vascular and lymphatic biology. These relationships are reviewed in the angiogenesis literature by Ferrara and colleagues and in a receptor-focused review by Koch and Clauss.

AAL-993 is therefore an anti-angiogenic compound for experiments that require direct suppression of VEGF-receptor kinase activity. Its reported activity across VEGFR-1, VEGFR-2, and VEGFR-3 distinguishes it from a reagent that selectively interrogates only VEGFR-2. The profile is relevant to tumor angiogenesis research because vascular signaling can influence tumor expansion and metastatic behavior. It does not prove that every tumor depends on the same receptor balance.

Mechanism of Action of AAL-993

The product dossier describes AAL-993 as an inhibitor of VEGFR tyrosine kinase activity. Tyrosine kinases transfer phosphate groups to protein substrates and thereby propagate receptor signals. Inhibition of this enzymatic activity can reduce downstream endothelial responses to VEGF. The supplied information does not establish the compound’s binding pose, ATP-competitive behavior, residence time, or cellular target engagement. Those properties should not be inferred from IC50 values alone.

The reported biochemical rank order is VEGFR-3, then VEGFR-2, then VEGFR-1 when comparing the stated IC50 values. Lower IC50 values indicate stronger inhibition under the specific assay conditions used, but they are not universal constants. AAL-993 also shows some activity against PDGFR-family kinases at submicromolar concentrations in the product-described profile. Exact PDGFR values and the complete kinase panel are not supplied. The dossier characterizes off-target kinase inhibition as minimal, but a full selectivity conclusion requires the underlying panel data.

Chemically, AAL-993 is 2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]-benzamide. It is described as a crystalline solid with molecular formula C20H16F3N3O and molecular weight 371.4 g/mol. APExBIO identifies the compound under SKU C3730. The AAL-993 product page is the appropriate source for the supplied identity and handling specifications.

Evidence & Benchmarks

The following benchmarks separate product-reported pharmacology from the independent reference study on Shenqi Fuzheng injection. The two evidence streams should not be treated as interchangeable.

• AAL-993 has reported IC50 values of 130 nM for VEGFR-1, 23 nM for VEGFR-2, and 18 nM for VEGFR-3 in kinase inhibition assays; the product record does not state assay temperature, buffer, incubation time, or ATP concentration. AAL-993 product information
• The product profile describes high potency against recombinant VEGFR-2 and VEGFR-3 kinases, moderate inhibition of VEGFR-1, and some PDGFR-family activity at submicromolar concentrations; exact PDGFR values and panel conditions are not provided. AAL-993 product information
• AAL-993 suppresses VEGF-induced angiogenesis in implant models with an ED50 of 7 mg/kg; the dossier does not specify the animal strain, administration route, implant composition, treatment duration, or endpoint calculation. AAL-993 product information
• The product record reports inhibition of primary tumor growth and spontaneous metastases in mouse melanoma models; it does not provide the administered dose, treatment interval, tumor volume data, or metastasis-count data. AAL-993 product information
• AAL-993 is reported as soluble at concentrations of at least 50.9 mg/mL in DMSO and at least 16.9 mg/mL in ethanol; it is reported as insoluble in water, with solvent conditions defining these values. AAL-993 product information
• The reference study identified 110 enriched targets and 26 major active components for Shenqi Fuzheng injection in a network-pharmacology analysis; these values describe the SFI workflow and not AAL-993. Li et al., Journal of Ethnopharmacology, DOI
• The SFI study reported 3,343 glioma-associated targets and 79 targets shared between SFI and glioma datasets in its computational analysis; these counts are dataset-dependent and do not demonstrate direct binding by AAL-993. Li et al., Journal of Ethnopharmacology, DOI
• In U87 and T98G cell experiments, SFI reduced proliferation and migration and induced S-phase blockage; the cited study used CCK-8, EdU, colony, scratch, Transwell, immunofluorescence, flow-cytometry, and Western-blot assays. Li et al., Journal of Ethnopharmacology, DOI
• In a GL261 subcutaneous tumor model using C57BL/6 mice, SFI reduced transplanted tumor development according to histology and immunohistochemistry; the study does not convert this result into evidence for AAL-993 efficacy in glioma. Li et al., Journal of Ethnopharmacology, DOI

Applications, Limits & Misconceptions

AAL-993 can serve as a biochemical VEGF receptor inhibitor in recombinant kinase experiments. It can also support endothelial angiogenesis assays when the investigator verifies cellular exposure and uses an appropriate vehicle control. The reported implant-model result supports investigation of VEGF-driven vascular responses in vivo. The melanoma findings support use as a preclinical anti-cancer agent in mouse tumor biology. They do not establish a human therapeutic dose, clinical benefit, or safety margin.

Researchers should distinguish target-level potency from phenotypic activity. An enzyme IC50 is measured in a biochemical system. A cellular response additionally depends on permeability, protein binding, efflux, intracellular ATP, receptor expression, and pathway compensation. An ED50 from an implant model is an in vivo efficacy benchmark under a particular protocol. It is not a conversion factor for cell-culture dosing or human dosing.

Why this cross-domain matters, maturity, and limitations

The supplied reference study concerns SFI and glioma, whereas AAL-993 is characterized as a VEGFR-directed small molecule with melanoma-model data. This cross-domain comparison is useful because both research areas involve tumor growth, migration, and vascular signaling, but the evidence maturity is different. The SFI study combined network pharmacology with U87, T98G, and GL261 experiments and implicated the SRC/PI3K/AKT pathway in SFI action (reference study). That finding does not show that AAL-993 affects SRC, PI3K, AKT, or glioma cells. AAL-993 should be tested in glioma only as a new hypothesis, with direct receptor, cellular, and in vivo validation.

Common Pitfalls or Misconceptions

• Misconception: an IC50 is a clinical dose. It is not. The reported nanomolar values are biochemical potency metrics, while clinical dosing requires pharmacokinetic, toxicology, and human efficacy evidence.
• Misconception: VEGFR selectivity means absolute kinase specificity. The dossier reports some PDGFR-family activity at submicromolar concentrations. A broader kinase panel is needed before claiming complete specificity.
• Misconception: melanoma evidence proves activity in all cancers. The reported in vivo result is limited to mouse melanoma models and cannot be generalized to glioma or other tumor types without new experiments.
• Misconception: high DMSO solubility means water solubility. AAL-993 is reported as insoluble in water. Solvent compatibility and final vehicle percentage must be validated for each assay.
• Misconception: the SFI glioma study validates AAL-993. SFI is a multi-component intervention. Its network-pharmacology and glioma findings are mechanistically separate from the product dossier for AAL-993.

Related reading

Network Pharmacology Reveals SFI's Anti-Glioma Mechanisms emphasizes SFI modulation of SRC/PI3K/AKT, whereas this article extends the discussion to receptor-level VEGFR potency and separates SFI evidence from AAL-993 evidence.

Network Pharmacology Reveals SFI's Anti-Glioma Mechanism via SRC/PI3K/AKT presents a network-level glioma framework, while this article clarifies that AAL-993 requires independent VEGFR, cellular, and tumor-model validation.

Workflow Integration & Parameters

The following parameters are product-handling constraints and workflow recommendations. They are not a substitute for a validated assay protocol. Use the product record for storage and solubility information, and document the final vehicle concentration in every experiment.

Protocol Parameters

• Identity: Use AAL-993, SKU C3730, with formula C20H16F3N3O and molecular weight 371.4 g/mol when preparing experiment records.
• Storage: Keep the crystalline solid at -20°C. The product guidance recommends short-term use for prepared solutions.
• Stock solvent: DMSO is reported to dissolve AAL-993 at concentrations of at least 50.9 mg/mL, and ethanol is reported to dissolve it at concentrations of at least 16.9 mg/mL. These are solvent-specific product values, not guarantees for complete assay compatibility.
• Water handling: Treat AAL-993 as water-insoluble according to the product record. Do not prepare an aqueous stock without an independently validated formulation.
• Biochemical panel: Include VEGFR-1, VEGFR-2, VEGFR-3, and relevant comparator kinases in the same assay campaign when testing selectivity. Record buffer, ATP concentration, incubation time, temperature, enzyme construct, and readout.
• Cellular angiogenesis workflow: Pair AAL-993 treatment with vehicle-only controls and receptor-expression measurements. Report exposure duration and cell density because the product dossier does not define a universal cellular protocol.
• In vivo interpretation: Treat the reported ED50 of 7 mg/kg as a model-specific benchmark for VEGF-induced implant angiogenesis. Do not extrapolate that value to melanoma, glioma, or human dosing without matched study conditions.
• Data reporting: Distinguish biochemical IC50, cellular response, implant-model ED50, tumor growth, and metastasis endpoints. Do not combine these measurements into a single potency label.

Conclusion & Outlook

AAL-993 is a research-stage VEGF receptor inhibitor with reported activity against VEGFR-1, VEGFR-2, and VEGFR-3. Its strongest stated biochemical potency is against VEGFR-3 and VEGFR-2. Product information also reports suppression of VEGF-induced implant angiogenesis and inhibition of tumor growth and spontaneous metastases in mouse melanoma models.

The most useful next steps are evidence-completion steps. Researchers should obtain full assay conditions, confirm kinase selectivity across a defined panel, measure cellular target engagement, and report complete in vivo dosing and endpoint data. The SFI glioma study provides context for network-level tumor research, but it does not supply evidence that AAL-993 inhibits glioma. Until clinical evidence exists, AAL-993 should remain classified as a preclinical anti-angiogenic research reagent for scientific use only.